^
Association details:
| Biomarker: | BCL2 fusion + EZH2 mutation |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + Tazverik (tazemetostat) (EZH2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Combined EZH2 and BCL2 Inhibitors As Precision Therapy for Genetically Defined DLBCL Subtypes
Published date:
11/06/2019
Excerpt:
In DLBCL cells with both a BCL2 translocation and EZH2 mutation, the combination resulted in increased killing compared to either drug alone (Figure 1, SUDHL6 (p<0.005), WSU-DLCL2 (p<0.005), and OCI-LY1 (p<0.005)).
DOI:
10.1182/blood-2019-126790
